Metabolic receptor research
Retatrutide
Triple GLP-1 / GIP / glucagon receptor agonist
Account required· quoted per order
Size
| Molecular formula | C221H342N46O68 |
|---|---|
| Sequence | 39 aa (acylated, C20 diacid) |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC / MS) |
| Storage | −20 °C, protect from light |
| Use | Laboratory research only |
For laboratory research use only. Not for human or veterinary use. Not a drug, supplement, or cosmetic. No dosing, administration, or use guidance is provided.
About this compound
Identity & research context
Retatrutide (LY3437943) is a synthetic 39-amino-acid, C20 fatty-diacid-acylated peptide engineered as a simultaneous agonist at the GLP-1, GIP, and glucagon receptors. It has been investigated in preclinical and in-vitro model systems as a reference tool compound for studying coordinated triple incretin/glucagon receptor co-activation. Retatrutide is an investigational compound and is not an approved drug.
Key research points
- Body-weight & energy-expenditure endpoints (DIO rodent models)
- Glucose-regulation research (animal models)
- Glucagon-receptor co-activation research
- Metabolic & hepatic-fat markers (preclinical)
References
For research purposes only. Not FDA approved. Information shown is sourced from published peer-reviewed literature for educational reference only — not medical advice or product claims. Read the full disclaimer.
Also in the catalog
View all